NASDAQ:ITRM - Iterum Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.27 -0.33 (-4.34 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$7.27
Today's Range$7.27 - $7.60
52-Week Range$4.70 - $13.00
Volume8,170 shs
Average Volume21,418 shs
Market Capitalization$101.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive ITRM News and Ratings via Email

Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITRM
CUSIPN/A
Phone353-1903-8920

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00

Profitability

Miscellaneous

EmployeesN/A
Market Cap$101.49 million
Next Earnings Date3/27/2019 (Estimated)
OptionableNot Optionable

Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics PLC (NASDAQ:ITRM) issued its earnings results on Wednesday, November, 14th. The company reported ($1.24) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.97) by $0.73. The company earned $0.25 million during the quarter. View Iterum Therapeutics' Earnings History.

When is Iterum Therapeutics' next earnings date?

Iterum Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Iterum Therapeutics.

What price target have analysts set for ITRM?

5 analysts have issued 12 month price objectives for Iterum Therapeutics' shares. Their predictions range from $18.00 to $24.00. On average, they anticipate Iterum Therapeutics' share price to reach $20.75 in the next year. This suggests a possible upside of 185.4% from the stock's current price. View Analyst Price Targets for Iterum Therapeutics.

What is the consensus analysts' recommendation for Iterum Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iterum Therapeutics.

Has Iterum Therapeutics been receiving favorable news coverage?

Headlines about ITRM stock have trended negative on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Iterum Therapeutics earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.

Who are some of Iterum Therapeutics' key competitors?

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Innovate Biopharmaceuticals (INNT), Viking Therapeutics (VKTX), Snap (SNAP), Alibaba Group (BABA), QUALCOMM (QCOM), Anavex Life Sciences (AVXL), Encana (ECA), Krystal Biotech (KRYS), Puma Biotechnology (PBYI) and Intellia Therapeutics (NTLA).

Who are Iterum Therapeutics' key executives?

Iterum Therapeutics' management team includes the folowing people:
  • Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)
  • Ms. Judith M. Matthews, Chief Financial Officer (Age 49)
  • Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)
  • Mr. Benjamin M. Pe, VP of Operations
  • Mr. John J. White, VP of Bus. Devel. & Supply Chain

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.25%). Company insiders that own Iterum Therapeutics stock include Corey N Fishman, David George Kelly, Judith M Matthews, Mark Chin, Michael W Dunne, Patrick J Heron, Paul R Edick and Sofinnova Venture Partners Ix,. View Institutional Ownership Trends for Iterum Therapeutics.

Which major investors are selling Iterum Therapeutics stock?

ITRM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Iterum Therapeutics.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $7.27.

How big of a company is Iterum Therapeutics?

Iterum Therapeutics has a market capitalization of $101.49 million and generates $500,000.00 in revenue each year.

What is Iterum Therapeutics' official website?

The official website for Iterum Therapeutics is http://www.iterumtx.com.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected]


MarketBeat Community Rating for Iterum Therapeutics (NASDAQ ITRM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about Iterum Therapeutics and other stocks. Vote "Outperform" if you believe ITRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITRM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel